Celltrion
South Korea's leading biosimilar manufacturer challenging global pharma giants
Company Overview
Celltrion is South Korea's largest biopharmaceutical company and a global pioneer in biosimilar development. The company developed the world's first antibody biosimilar (Remsima/Inflectra) and has built a portfolio of biosimilars for autoimmune diseases, oncology, and ophthalmology. Celltrion's vertically integrated model — from development through manufacturing to direct commercialization — has disrupted the traditional pharmaceutical value chain.
이 기업이 중요한 이유
Celltrion has proven that Asian companies can compete with global pharma giants in complex biologic drug development, opening new markets for affordable biologics.
핵심 집중 분야
동종 기업
시그널 활동
Signal Timeline
2 건Celltrion Commences Full-Scale CMO Production at U.S. Facility
Celltrion has begun full-scale production of Eli Lilly CMO products at its U.S. Branchburg facility, following acquisition and site preparations completed by January 2026. The company is also initiating validation for its own product manufacturing, aiming for a fully integrated U.S. supply system. This move is part of a strategy to mitigate U.S. tariff risks through local production and inventory.
Celltrion Announces 35th Annual General Meeting of Shareholders
Celltrion has announced its 35th Annual General Meeting of Shareholders, scheduled for March 24, 2026, at 10:00 AM KST in Incheon, Republic of Korea. Key agendas include reporting on the fiscal year 2025 audit and business, approving financial statements, amending articles of incorporation, electing directors and audit committee members, and approving director remuneration and treasury share plans.
이 기업의 새로운 시그널이 게시되면 알림을 받습니다.